Development of ELISA based detection system for lethal toxin of *Clostridium sordellii*

Preetika Arya, S. Ponmariappan, Lokendra Singh* & Om Kumar

*Biotechnology Division, Defence Research & Development Establishment, Gwalior, India*

Received October 3, 2011

**Background & objectives:** *Clostridium sordellii* and its toxins are associated with diseases in animals as well as human. *C. sordellii* produces two protein toxins (lethal toxin and haemorrhagic toxin). Lethal toxin has gained more importance due its high toxicity. The present study was carried out to develop a sandwich ELISA for detection of lethal toxin of *C. sordellii*.

**Methods:** The catalytic domain (1.6kb) of lethal toxin of *C. sordellii* was PCR amplified, cloned into pQE30 UA vector and transformed into *Escherichia coli* SG 13009. Expression conditions were optimized and the recombinant protein was purified under native condition using Ni-NTA affinity chromatography, confirmed by SDS-PAGE and Western blot. Antibody was generated against the purified recombinant protein using Freund’s complete and incomplete adjuvants (FCA and FIA) in BALB/c mice and rabbit. A sandwich ELISA was optimized for the detection of lethal toxin.

**Results:** The maximum recombinant protein expression was achieved at 0.5 mM IPTG (isopropylthiogalactoside) induction 4.0 h of post-induction. The polyclonal antibody raised in mice and rabbit showed a titre up to 1:512000. The produced antibody was highly sensitive with the detection limit of 0.3 ng/ml of lethal toxin at 1:4000 dilutions of mice (capturing) and rabbit (revealing) antibody.

**Interpretation & conclusions:** An ELISA based detection system was developed for the detection of lethal toxin of *C. sordellii*. The developed detection system was found to be specific as there was no cross-reactivity with any other clostridial toxins. It will be useful for the detection of lethal toxin of *C. sordellii* in clinical and environmental samples.

**Key words** *Clostridium sordellii* - ELISA - lethal toxin - recombinant protein - toxic shock syndrome

*Clostridium sordellii* is an anaerobic, Gram positive, spore forming rod which typically resides in soil and colonizes the gastrointestinal tract and genital tracts of healthy human. It produces two antigenically different protein toxins *i.e.* lethal toxin (LT) and haemorrhagic toxin (HT). The lethal toxin is a single chained protein of about 270 kDa and exhibits ABCD model (A, biological activity; B, binding; C, cutting; D,delivery). It consists of four domains, receptor binding domain, catalytic domain, transmembrane domain and cysteine protease domain. The receptor-binding domain is located at the C-terminus region.

*Present address:* Defence Research Laboratory, Tezpur, Assam.
and responsible for binding to the target cell and its uptake by receptor mediated endocytosis. The catalytic domain is located at the N-terminus region of the toxin and causes the mono-glucosylation of low molecular weight Guanosine-5' triphosphate (GTP) binding proteins of Rac, Cdc 42 and Ras subfamily including H-Ras, R-Ras, Ral and Rap\textsuperscript{2}. The transmembrane domain is located in between these two domains and responsible for translocation of the toxin from endosome to cytoplasm. The cysteine protease domain is located in between the catalytic domain and transmembrane domain and responsible for the autocatalytic processing of lethal toxin. The catalytic domain glucosylates low molecular weight GTP binding proteins using co-substrate uridine di phosphate (UDP)-glucose and renders these inactive and inhibiting the recognition of their downstream proteins. In the case of Rac, and Cdc, modification impairs actin cytoskeleton assembly and organization leading to the massive capillary leakage which is the characteristic of \textit{C. sordellii} infection\textsuperscript{3}. Lung and heart are the preferential organs for action of lethal toxin of \textit{C. sordellii}\textsuperscript{4}.

The lethal toxin has been associated with a number of diseases including toxic shock syndrome (TSS) in post abortion and postpartum cases\textsuperscript{5,6}, bacteremia\textsuperscript{7}, toxic omphalitis in infants\textsuperscript{8}, sudden death syndrome, septic arthritis\textsuperscript{9} and necrotizing fasciitis\textsuperscript{10}. Recently, \textit{C. sordellii} has been reported as a cause of acute constrictive pericarditis with pyopericardium and tamponade\textsuperscript{11}. The list of diseases has increased with the implication of this organism in death of drug users by contaminated heroin\textsuperscript{12} and the patients receiving musculoskeletal allograft\textsuperscript{12}. It causes enteritis and sudden death in sheep\textsuperscript{13-16}. It also causes diarrhea and enteric lesions in calves\textsuperscript{17}. The early human clinical symptoms of \textit{C. sordellii} infection are haematuria, increased WBC, increased platelet counts, decreased serum calcium and protein levels. As infection progresses, it induces six distinct clinical features which include a marked leukocytosis known as leukemoid reaction, refractory hypotension, severe tachycardia, profound capillary leak syndrome and haemococoncentration\textsuperscript{1}.

Cell culture based cytotoxicity assay is considered as the gold standard for the detection of lethal toxin. The testing time of cell culture based cytotoxicity assay requires at least 48-72 h. This disadvantage limits the usage of this diagnostic assay, in addition, maintenance of cell lines is expensive, the assay format is complex and it is difficult to obtain quantitative results. Alternate to the cell culture cytotoxicity assay, ELISA is considered as one of the most sensitive, easy and amenable method to develop a high throughput system. In the present study, an attempt was made to develop a sandwich ELSIA using polyclonal antibodies raised against the recombinant protein of lethal toxin of \textit{C. sordellii}.

**Material & Methods**

The work was carried out in the Biotechnology Division of Defence Research and Development Establishment (DRDE), Gwalior.

**Cloning and expression:** The genomic DNA of \textit{C. sordellii} ATCC 9714 was isolated using DNA purification kit from Promega (USA) according to the manufacturer’s protocol. The forward primer \textit{LT f}: 5'-AAC TTA GTT AAC AAA GCC CAA-3' and reverse primer \textit{LT r} 5'-TTA TTA TAA TAT TTT TTT AGAAAC ATAAAATC-3’ specific for the catalytic domain of the lethal toxin gene were synthesized from Sigma (Bangalore) and the gene was PCR amplified. All PCR reactions\textsuperscript{18} were carried out for an initial denaturation at 94ºC for 5 min followed by 30 cycles consisting of denaturation at 94ºC for 1 min, annealing for 1 min at 58ºC, extension at 72ºC for 2 min and final extension at 72ºC for 10 min in a thermal cycler (Tgradient, Biometra, Germany). The amplified PCR product was checked by 1 per cent agarose gel electrophoresis. The PCR product was further purified using DNA purification kit (Qiagen, Germany) as suggested by the manufacturer’s protocol. The PCR product was quantified using Nanodrop (USA). The purified PCR product was ligated with the prelinearized expression vector pQE 30 UA (Qiagen, USA) and the chimeric vector was transformed into electro competent \textit{Escherichia coli} SG 13009 using an electroporator (Gene pulser XL, Bio-Rad, USA). The positive transformants were selected on Luria Bertani (LB) agar plates (Difco, USA) containing kanamycin (30 µg/ml) and ampicillin (100 µg/ml). Plasmids were extracted from the selected transformants using QIA miniprep kit (Qiagen, Germany) following manufacture’s protocol. Further, these plasmids were screened for the confirmation of the presence of inserts using LT gene specific primers mentioned above and also checked inframe using the combination of LT gene specific and pQE 30 UA vector specific primers.

**Recombinant protein expression and localization:** The selected transformant was inoculated into 5ml LB broth containing kanamycin (30 µg/ml) and
ampicillin (100 µg/ml) and grown overnight at 37°C with constant shaking. One per cent of the overnight grown culture was further inoculated in 30 ml LB broth containing respective antibiotics and grown at 37°C. Growth was monitored by measuring the absorbance OD_{600}. Approximately at OD_{600} 0.6 -0.8 the recombinant protein expression was induced with different concentrations (0.25, 0.5, 0.75, 1 mM) of isopropylthiogalactoside (IPTG) and the growth was resumed for 4.0 h under the same conditions. Prior to IPTG induction, 2 ml aliquots were taken out aseptically to be used as uninduced control. After induction, 2ml samples were withdrawn at every one hour interval and cells were harvested by centrifugation at 8000 x g for 10 min at 4°C. Each sample was analyzed by 12 per cent SDS -PAGE using molecular weight marker (Fermentas, Canada). Localization of the recombinant protein was done by solubilizing the induced cell pellet in phosphate buffer (50mM NaH_{2}PO_{4}, 300 mM NaCl, 10m Mimidazole) at the ratio of 1:5 (w/v). Lysozyme (1mg/ml) was added to the cell lysate and it was kept in ice for 30 min and then frozen at -20°C. After thawing it was sonicated by 9 sec pulses with 9 sec pause for 10 min. The cell lysate was centrifuged at 10000xg for 40 min at 4°C and supernatant and pellet were checked for the presence of the recombinant protein on 12 per cent SDS-PAGE^{19}.

**Purification of recombinant lethal toxin (rLT) protein:** Supernatant was used for the purification of recombinant lethal toxin protein using affinity chromatography. One ml of Ni-NTA slurry (Qiagen, Germany) was packed into the column and it was equilibrated using the equilibration buffer (50 mM NaH_{2}PO_{4}, 300 mM NaCl, and 10 mM imidazole) and 5 ml of supernatant (supernatant + 20mM β-ME, 2% Triton X-100) was loaded on to it. Column was left for 30 min at room temperature with lysate and in between Ni-NTA slurry was mixed gently to allow binding. The column was washed with 10-12 volumes of wash buffer (50 mM NaH_{2}PO_{4}, 300 mM NaCl, 60 mM imidazole and 2% Triton) and then the protein was eluted with elution buffer (250 mM NaH_{2}PO_{4}, 300 mM NaCl, 250 mM imidazole). Different elutes were collected and checked on 12% SDS-PAGE along with different washes and flow through. The collected elutes were pooled together and dialyzed against the phosphate buffer saline (PBS). Finally, the dialysed protein was concentrated using an Amicon ultra cell with 30kDa cut off membrane (Millipore, USA). The protein concentration was determined using BCA protein assay kit (Sigma, USA).

**Western blot analysis:** The rLT protein is tagged with His6 fusion protein and to confirm the presence of purified protein, commercially available anti-His monoclonal antibody (Qiagen, Germany) was used. Purified recombinant protein was run on 12 per cent denaturing gel (SDS-PAGE), along with prestained molecular weight marker (MBI Fermentas, Canada) on adjacent lanes and transferred electrophoretically to the nitrocellulose membrane (Millipore, USA). The membrane was incubated in 3 per cent bovine serum albumin (BSA, fraction V) in PBS at 4°C for overnight. The nitrocellulose membrane was washed three times with PBS containing 0.05 per cent Tween-20 (PBS-T) and once with PBS and then incubated at 1:1000 dilution of mouse anti-His-monoclonal antibody for 1.0 h with gentle shaking. The membrane was again washed three times with PBS-T and once with PBS and then the membrane was incubated in 1:2000 dilution of rabbit anti-mouse IgG horseradish peroxidase (HRP) (Dako, Denmark) as secondary antibody with gentle shaking at room temperature for 1.0 h. The membrane was washed and the protein bands were visualized by incubating the membrane in 3,3'-diaminobenzidine in PBS containing 8.8mM H_{2}O_{2}^{20}.

**Antibody generation:** The study protocol was approved by the Institutional Ethics Committee of DRDE. BALB/c mice (approximately 16-22 g), Australian white rabbit (approximately 1-2-1.8 kg) were selected for the production of polyclonal antibody in both mice and rabbit. A group of eight mice was immunized intraperitonially with 10µg and one rabbit was immunized subcutaneously with 100 µg of purified rLT with Freund’s complete adjuvant (FCA) (Sigma, Aldrich, USA). The priming was followed by booster immunizations on days 7, 14, 21 days with increasing concentrations of protein with Freund’s incomplete adjuvant (FIA) (Sigma, Aldrich, USA). Total volume used per mouse at each immunization was 100 µl and rabbit 500 µl. Blood was collected from retro-orbital plexus of mice with heparinised capillaries and from the heart of the rabbit before the first dose and four days after the last dose. The collected blood was incubated at 37°C for 30 min and subsequently incubated at 4°C for 1 h. The serum was collected after the centrifugation of the blood samples at 600 x g for
10 min to get rid of residual blood cells. All serum samples were stored at -80°C for further studies.

**Indirect enzyme-linked immunosorbert assay (ELISA):** The collected serum was tested for the recognition of rLT by ELISA. Microtitre plates (Nunc-Immuno plate with Maxisorp surface, Nunc, Roskilde, Denmark) were coated with 500ng/well of rLT protein in coating buffer (0.05M carbonate-bicarbonate buffer pH 9.6) and incubated overnight at 4°C. The plates were blocked with 300µl of 3 per cent BSA in PBS for 2.0 h at 37°C. Plates were washed three times with PBS-T and once with PBS. Mouse anti-rLT and rabbit anti-rLT test serum samples were serially diluted to twofold in 1 per cent BSA in PBS starting from 1:1000 to 1:20,48,000 and incubated in duplicate wells (100 µl/ well) at 37°C for 1.0 h. The plate was washed as above. The rabbit anti-mouse IgG-HRP (Dako, Denmark) and goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology, USA) diluted 1:2000 in 1 per cent BSA in PBS were added to the wells (100 µl/well) and incubated at 37°C for 1.0 h. After washing, the plates were developed by adding 2, 2’-azino-bis(3-ethylbenzo-thiazoline-6-sulphonic acid) diammonium salt solution containing H2O2, and it was incubated at 37°C for 25 min (100 µl/ well). The absorbance was measured at 410 nm (A 410) using an ELISA plate reader (Biotek, USA). Mean A 410 values and standard errors of the mean (SEM) for each group were calculated. Dilutions of the serum samples at which the absorbance value was two times the cut-off value (A 410 using the preimmune serum) were considered to be the ELISA endpoint. The cut-off value for assay was calculated as the mean specific optical density plus three times the standard deviation (SD) for pre-immune serum assayed at a dilution of 1:1000. The cross-reactivity of the raised antibody with other clostridial species was checked by coating the microtitre plates with 2µg of the trichloroacetic acid (TCA) precipitated culture supernatant of C. sporogenes ATCC-11437, C. perfringens ATCC-13124 (from ATCC, USA) C. tetani 49205 (from CRI, Kasauli), C. difficile, Staphylococcus aureus and Shigella dysenteriae (from culture collection Biotechnology Division, DRDE, Gwalior). For S. aureus and S. dysenteriae cell lysates were used.

**Sandwich enzyme-linked immunosorbent assay (ELISA):** The optimum dilutions of mice and rabbit anti-rLT serum were determined through checkerboard titration and 1:4000 dilutions were found suitable for sandwich ELISA. Further, the raised mice anti-rLT antibody was diluted to 1:4000 in coating buffer and used to coat the polystyrene wells (100µl/well) in duplicates and incubated overnight at 4°C. After decanting the wells, the remaining sites of adsorption were blocked by addition of 3 per cent BSA in PBS, 300 µl/well and incubated for 2 h at 37°C. Then the wells were washed three times with PBS-T and once with PBS. Purified rLT (100 µl/well) serially diluted (10 µg to 0.0375 ng/ml) in PBS containing 1 per cent BSA was added to the blocked antibody coated wells and incubated for 1 h at 37°C. The wells were washed as mentioned above. Again the wells were incubated with raised rabbit anti-rLT antibody (100 µl/well) at the dilution of 1:4000 in 1 per cent BSA in PBS and incubated at 37°C for 1 h. The wells were washed as above and further incubated at 37°C for 1 h with the HRP-conjugated goat anti-rabbit IgG at a dilution of 1:2000. The wells were washed three times with PBS-T and once with PBS. The cut-off value for assay was calculated as the mean specific optical density plus three times the standard deviation (SD) of the well having no antigen. Concentration of the recombinant lethal toxin at which the absorbance value was two times the cut-off value (A 410 using the well having no antigen) was considered to be the ELISA endpoint.

**Results**

**Cloning, expression and purification of recombinant protein:** The amplified PCR product (1.6 kb) was highly specific to the catalytic domain of the lethal toxin gene of C. sordellii, was confirmed by double pass sequencing followed by multiple sequence alignment with standard lethal toxin gene sequence available in NCBI database. The purified PCR product was cloned in pQE30 UA expression vector which is having a Histidine tag in the N-terminal end and aids in the purification and detection of recombinant lethal toxin protein. After ligation, the recombinant vector was transformed into the E. coli SG 13009. Plasmid was isolated from the selected transformant and checked for the presence of insert using LT gene specific forward and reverse primers. The recombinant protein expression conditions were optimized. The maximum yield of recombinant protein was obtained at OD600 0.6 with 0.5 mM IPTG induction with minimum incubation of 4.0 h after induction. Thereafter, the cells were harvested and subjected to localization studies. The results revealed that the majority of the recombinant lethal toxin protein was present in the supernatant and was confirmed by Western blot analysis with anti-
culture supernatant of C. difficile, C. sporogenes, C. perfringens and C. tetani. Similarly, no cross-reactivity was observed with cell lysate of S. aureus and S. dysenteriae. Similarly, no cross-reactivity was observed with cell lysate of S. aureus and S. dysenteriae.

**Evaluation of detection limit:** The recombinant protein was assayed in the concentration ranges from 10 µg to 0.0375 ng/ml to determine the limit of detection in the ELISA format. Mice anti-rLT specific antibody was used to capture the antigen at 1:4000 dilution and rabbit anti-rLT specific antibody were used to reveal the antigen at 1:4000 dilutions. Results showed that the rLT could be detected up to a concentration of approximately 0.3 ng/ml with the cut-off value of >0.129 (Fig. 3).

**Discussion**

*C. sordellii* is an important human pathogen which causes a number of diseases. The most fatal among these is fulminant toxic shock syndrome in post partum and post-abortion cases. In Canada, the number of
medically induced abortions (MIA) associated with mifepristone and misoprostal cases has been shown to be increasing. Apart from that, ten cases of soft tissue infections among injection drug users (IDU) were reported at different time period which were mainly caused by *C. sordellii*. Sensitive and rapid detection of lethal toxin is essential to save the life of the patients. Currently, the most reliable method for detection of lethal toxin is cell culture based cytotoxicity assay, while this assay is sensitive but it is slow, expensive and requires animal cell culture facilities and skilled manpower to perform the tests. As such there is no commercial detection system available for the specific detection of lethal toxin. In the present study, we developed an ELISA based detection system alternate to the *in vitro* system for the detection of lethal toxin in clinical and environmental samples.

Only a few studies have been carried out on lethal toxin of *C. sordellii*, the native lethal toxin (LT) was purified from the culture supernatant of *C. sordellii* IP82 by DEAE-Trisacryl, Ultrogel AcA3-4 gel filtration and hydroxyapatite column chromatography. The molecular weight of purified LT was estimated to be 240 to 250kDa and the isoelectric point (pI) was 4.55. The study concluded that antibodies raised against *C. sordellii* LT neutralized *C. difficile* toxin B. Cloning of the gene enabled us to have the sufficient amount of the protein without handing the pathogenic culture and it facilitated its purification as a tagged protein. In the present study, a fragment of lethal toxin gene was cloned in pQUE30 UA and expressed in *E. coli* SG 13009 to develop an ELISA based detection system. Similarly, Dreger et al. have cloned the gene encoding for the catalytic domain of lethal toxin of *C. sordellii* in pGex expression system with GST-fusion protein to prove that the cytotoxic effects of TcsL depend on the glucosylation of critical substrate proteins rather than on the glucosyltransferase activity. Mesmin et al. cloned the catalytic domain into pET-28 and expressed as His tagged protein to show the glucosyltransferase domain of lethal toxin of *C. sordellii*.
In the present study, we produced a high titre (1:512000) antibody which did not show any cross-reactivity with *C. difficile* and other closely related clostridia toxins. Similar kind of assay was developed from the inactivated whole lethal toxin of *C. sordellii* and the antibody showed cross reactivity with *C. difficile* toxin B but in the meantime it can also neutralize the cytotoxicity of *C. difficile*. The raised capture antibody against the catalytic domain of lethal toxin of *C. sordellii* was able to detect the lethal toxin up to concentration of approximately 0.3 ng/ml. The developed ELISA system is specific, rapid and can be used for the testing of a large number of samples. The more sensitive and rapid molecular techniques have been used for the detection of *C. sordellii* and lethal toxin gene from clinical specimens. Valour *et al.* isolated *C. sordellii* from brain abscess and confirmed by 16S rRNA gene sequencing. Highet *et al.* made an attempt for the direct PCR based detection of *C. sordellii* lethal toxin gene from the intestinal flora of infants who died from the sudden infant death syndrome but failed to detect by PCR. These methods are ultrasensitive in pure culture based studies, but when it comes to the clinical and environmental samples, these techniques fail to detect toxin due to the presence of PCR inhibitors. It requires expertise to clean up the samples to get true positive results.

In conclusion, an antibody based immuno detection system was developed for the detection of lethal toxin of *C. sordellii*. The generated high titre antibody will be highly useful for the detection of lethal toxin of *C. sordellii* from clinical and environmental samples.

**Acknowledgment**

Authors thank the Director, DRDE, Gwalior, for providing necessary facilities and support required for this study. Authors are also thankful to Dr Pravin Kumar, Animal Facility of DRDE, Gwalior, for providing animals.

**References**

1. Aldape MJ, Bryant AE, Stevens DL. *Clostridium sordellii* infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. *Clin Infect Dis* 2006; 43: 1436-46.

2. Aktories K, Just I. Clostridial Rho-inhibiting protein toxins. *Curr Top Microbiol Immunol* 2005; 291: 113-45.

3. Genth H, Hofmann F, Selzer J, Rex G, Aktories K, Just I. Difference in protein substrate specificity between hemorrhagic toxin and lethal toxin from *Clostridium sordellii*. *Biochem Biophys Res Commun* 1996; 229: 370-4.

4. Geny B, Khun H, Fitting C, Zarantonelli L, Mazuet C, Cayet N, *et al.* *Clostridium sordellii* lethal toxin kills mice by inducing a major increase in lung vascular permeability. *Am J Pathol* 2007; 170: 1003-17.

5. Sinave C, Le Templier G, Blouin D, Leveille F, Deland E. Toxic shock syndrome due to *Clostridium sordellii*: a dramatic postpartum and postabortion disease. *Clin Infect Dis* 2002; 35: 1441-3.

6. Rorbye C, Petersen IS, Nilas L. Postpartum *Clostridium sordellii* infection associated with fatal toxic shock syndrome. *Acta Obstet Gynecol Scand* 2000; 79: 1134-5.

7. Spera RV Jr, Kaplan MH, Allen SL. *Clostridium sordellii* bacteremia: case report and review. *Clin Infect Dis* 1992; 15: 950-4.

8. Adamkiewicz TV, Goodman D, Burke B, Lyerly DM, Goswitz J, Ferriero P. Neonatal *Clostridium sordellii* toxic encephalitis. *Pediatr Infect Dis J* 1993; 12: 253-7.

9. Gredlein CM, Silverman ML, Downey MS. Polymicrobial septic arthritis due to *Clostridium species*: case report and review. *Clin Infect Dis* 2000; 30: 590-4.

10. Kimura AC, Higa JJ, Levin RM, Simpson G, Vargas Y, Vugia DJ. Outbreak of necrotizing fasciitis due to *Clostridium sordellii* among black-tar heroin users. *Clin Infect Dis* 2004; 38: e87-91.

11. Chaudhry R, Verma N, Bahadur T, Chaudhary P, Sharma P, Sharma N. *Clostridium sordellii* as a cause of constrictive pericarditis with pyopericardium and tamponade. *J Clin Microbiol* 2011; 49: 3700-2.

12. Kainer MA, Linden JV, Whaley DN, Holmes HT, Jarvis WR, Jernigan DB, *et al.* *Clostridium* infections associated with musculoskeletal-tissue allografts. *N Engl J Med* 2004; 350: 2564-71.

13. Al-Mashat RR, Taylor DJ. *Clostridium sordellii* in enteritis in an adult sheep. *Vet Rec* 1983; 112: 19.

14. Clark S. Sudden death in periparturient sheep associated with *Clostridium sordellii*. *Vet Rec* 2003; 153: 340.

15. Lewis CJ, Naylor RD. Sudden death in sheep associated with *Clostridium sordellii*. *Vet Rec* 1998; 142: 417-21.

16. De Groot B, Dewey CE, Griffin DD, Perino LJ, Moxley RA, Hahn GL. Effect of booster vaccination with a multivalent clostridial bacterin-toxoid on sudden death syndrome mortality rate among feedlot cattle. *J Am Vet Med Assoc* 1997; 211: 749-53.

17. Al-Mashat RR, Taylor DJ. Production of diarrhea and enteric lesions in calves by the oral inoculation of pure cultures of *Clostridium sordellii*. *Vet Rec* 1983; 112: 141-6.

18. Mesmin B, Robbe K, Geny B, Luton F, Brandolin G, Popoff MR, *et al.* A phosphatidylserine-binding site in the cytosolic fragment of *Clostridium sordellii* lethal toxin facilitates glucosylation of membrane-bound Rac and is required for cytotoxicity. *J Biol Chem* 2004; 279: 49876-82.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 1970; 227: 680-5.

20. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci USA* 1979; 76: 4350-4.

21. Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol - United States and Canada, 2001-2005. *MMWR Morb Mortal Wkly Rep* 2005; 54: 724.

22. Baldacini O, Girardot R, Green GA, Rihn B, Monteil H. Comparative study of immunological properties and cytotoxic effects of Clostridium difficile toxin B and Clostridium sordellii toxin L. *Toxicon* 1992; 30: 129-40.

23. Popoff MR. Purification and characterization of *Clostridium sordellii* lethal toxin and cross-reactivity with *Clostridium difficile* cytotoxin. *Infect Immun* 1987; 55: 35-43.

24. Dreger SC, Schulz F, Huelsenbeck J, Gerhard R, Hofmann F, Just I, *et al.* Killing of rat basophilic leukemia cells by lethal toxin from *Clostridium sordellii*: critical role of phosphatidylinositol 3’-OH kinase/Akt signaling. *Biochemistry* 2009; 48: 1785-92.

25. Valour F, Boisset S, Lebras L, Martha B, Boibieux A, Perpoint T, *et al.* Clostridium sordellii brain abscess diagnosed by 16S rRNA gene sequencing. *J Clin Microbiol* 2010; 48: 3443-4.

26. Highet AR, Gibson CS, Goldwater PN. *Clostridium sordellii* lethal toxin gene is not detectable by PCR in the intestinal flora of infants who died from sudden infant death syndrome or other causes. *J Med Microbiol* 2010; 59: 251-3.

*Reprint requests: Dr S. Ponmariappan, Scientist, Biotechnology Division, Defence Research & Development Establishment Jhansi Road, Gwalior 474 002, India e-mail: ponmariappans@yahoo.com*